2015
Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial
Abstract: Aims:To investigate the efficacy and tolerability of empagliflozin added to basal insulin-treated type 2 diabetes. Methods: Patients inadequately controlled [glycated haemoglobin (HbA1c) >7 to ≤10% (>53 to ≤86 mmol/mol)] on basal insulin (glargine, detemir, NPH) were randomized to empagliflozin 10 mg (n = 169), empagliflozin 25 mg (n = 155) or placebo (n = 170) for 78 weeks. The baseline characteristics were balanced among the groups [mean HbA1c 8.2% (67 mmol/mol), BMI 32.2 kg/m 2 ]. The basal insulin dose was…
Search citation statements
Paper Sections
Select...
196
32
25
19
Citation Types
20
231
1
8
Year Published
2015
2025
Publication Types
Select...
227
20
6
2
Relationship
2
253
Authors
Journals
Cited by 256 publications
(260 citation statements)
References 41 publications
20
231
1
8
“…Overall, the effect of tofogliflozin add‐on to insulin therapy was favourable, and mostly consistent with previous long‐term studies on other SGLT2 inhibitors added to insulin . In line with previous studies on long‐term SGLT2 inhibitors added to insulin treatment, a subtle reduction in insulin was observed in this study . The rather small improvement in glucose observed in this study may explain the slight reduction in insulin, as the majority presumably did not require insulin reduction (HbA1c responder rates <7.0% and ≤6.5% at Week 52, 15.0% and 3.6%, respectively, in the tofo‐tofo group).…”
Section: Discussionsupporting
confidence: 90%
“…Overall, the effect of tofogliflozin add‐on to insulin therapy was favourable, and mostly consistent with previous long‐term studies on other SGLT2 inhibitors added to insulin . In line with previous studies on long‐term SGLT2 inhibitors added to insulin treatment, a subtle reduction in insulin was observed in this study . The rather small improvement in glucose observed in this study may explain the slight reduction in insulin, as the majority presumably did not require insulin reduction (HbA1c responder rates <7.0% and ≤6.5% at Week 52, 15.0% and 3.6%, respectively, in the tofo‐tofo group).…”
Section: Discussionsupporting
confidence: 90%
“…While some treatment‐by‐subgroup interactions were observed for the change in HbA1c at 16 weeks ( P =0.0195 for baseline HbA1c, P =0.0196 for BMI and P =0.0324 for renal function), the treatment effects of empagliflozin 10 mg or 25 mg versus placebo were generally consistent across subgroups. Both the baseline HbA1c and renal function subgroup interactions are in‐line with previous findings from studies of empagliflozin, which have shown a more pronounced effect in patients with higher baseline HbA1c and those with normal renal function. By contrast, the subgroup interaction observed for BMI was not expected but is probably attributable to the unexpectedly marked effect on HbA1c at 16 weeks observed with placebo in participants in the lowest BMI group (<25 kg/m 2 ).…”
Section: Discussionsupporting
confidence: 89%
“…These results are consistent with the two randomized controlled trials of add-on empagliflozin conducted in Caucasian patients, 18,19 both of which also employed different insulin dosing periods.…”
Section: Discussionsupporting
confidence: 87%
“…In the present study, the frequency of hypoglycaemia associated with tofogliflozin was higher (~30.0%) than that when tofogliflozin was administered as monotherapy (0% for a 20‐mg dose) . The increased risk of hypoglycaemia when tofogliflozin was administered with insulin is consistent with results for other SGLT2 inhibitors and with results for other SLGT2 inhibitors in Japanese patients . It is important to note that the insulin dose in the present study could only be changed if FPG was ≥240 mg/dL or patients experienced hypoglycaemia.…”
Section: Discussionsupporting
confidence: 87%
